
Marrow's lead candidate MAR-101 aims to reactivate fetal hemoglobin in sickle cell disease and beta thalassemia through in vivo bone marrow targeting.
An industrial biotechnology company in Denmark required more rigorous control measures to ensure a high level of bio-decontamination in its facility. An automated hydrogen peroxide vapor service from Bioquell was selected.






